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Abstract
Introduction: Nasopharyngeal Carcinoma (NPC) is a major health problem in southern and eastern Asia. In Indonesia NPC is
the most frequent cancer in the head and neck area. NPC is very sensitive to radiotherapy resulting in 3-year disease-free
and overall survival of approximately 70% and 80%, respectively. Here we present routine treatment results in a prospective
study on NPC in a top referral; university hospital in Indonesia.
Methods: All NPC patients presenting from September 2008 till January 2011 at the ear, nose and throat (ENT) department
of the Dr. Sardjito General Hospital, Universitas Gadjah Mada, Yogyakarta, Indonesia, were possible candidates. Patients
were included if the biopsy was a histological proven NPC without distant metastasis and were assessed during counselling
sessions prior to treatment, as being able to complete the entire treatment.
Results: In total 78 patients were included for treatment analysis. The median time between diagnosis and start of
radiotherapy is 120 days. Forty-eight (62%) patients eventually finished all fractions of radiotherapy. The median duration of
the radiotherapy is 62 days for 66 Gy. Median overall survival is 21 months (95% CI 18–35) from day of diagnosis.
Conclusion: The results presented here reveal that currently the treatment of NPC at an Indonesian hospital is not sufficient
and cannot be compared to the treatment results in literature. Main reasons for these poor treatment results are (1) a long
waiting time prior to the start of radiotherapy, (2) the extended overall duration of radiotherapy and (3) the advanced stage
of disease at presentation.
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Introduction
Cancer has become a leading cause of death and morbidity in
low and middle-income countries. While this has been recognized
for at least twenty years, healthcare systems in these countries
often cannot deliver the prevention and care needed to overcome
this challenge [1–4]. Most publications that address this issue are
based on cancer incidence and barely report on treatment results
and survival. The main reason for this is the lack of appropriate
data collection in developing countries. There is a clear need for
improved cancer control systems in developing country settings
[5]. Recently we have introduced a Clinical Trial Data
Management service (CTDMS) to monitor treatment results of
Nasopharyngeal Carcinoma (NPC) in a university hospital setting
in Yogyakarta, Indonesia [6].
In southern and eastern Asia NPC is a major health problem. In
Indonesia NPC is the most frequent cancer in the head and neck
area and ranks as the 4th most common tumour found in males.
The undifferentiated histological subtype, NPC WHO III, is the
most prevalent NPC type in South-East Asia and Indonesia. This
type of cancer is causally associated with the Epstein-Barr virus
(EBV) [7]. The incidence is estimated 6 per 100,000, leading to
12,000 new cases per year [8–10]. Due to the insufficient national
cancer registration system, the actual number is most probably
much higher. NPC is very sensitive to radiotherapy at early stage
(stage I–II), but this type of treatment is not generally available for
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many patients in developing countries and unfortunately can
induce complications after treatment if not properly administered.
Since the location of the tumour has a close contact with the base
of skull, the brain stem and spinal cord, radiation is hindered by
dose limitations on these organs at risk. For advanced NPC (stage
III–IV), standard-care is concurrent chemo radiation therapy with
high-dose radiation combined with cisplatin-based regimens. This
treatment approach may result in 3-year disease-free and overall
survival of approximately 70% and 80%, respectively [11,12]. A
recent meta-analysis confirmed the clinical benefit of concurrent
chemo radiation therapy (CCRT) compared with radiation alone
(RT) in the treatment of stage III and IV NPC in endemic areas
[13]. Nearly all treatment results on NPC presented in the
literature derive from top-end hospitals and clinical trial settings.
Here we present a prospective study on routine treatment results
of NPC at a university hospital in Indonesia.
Patients and Methods
Patients Eligibility
All NPC patients presenting from September 2008 till January
2011 at the ear, nose and throat (ENT) department of the Dr
Sardjito General Hospital, Universitas Gadjah Mada, Yogyakarta,
Indonesia, were analysed. Patients were examined by CT-scan,
chest X-ray, ultrasound of the abdomen and bone survey. Patients
were included in the study if the biopsy was a histological proven
NPC without distant metastasis and were assessed during
counselling sessions prior to treatment, as being able to complete
the entire treatment. Tissue analysis was performed at the
pathology department of the Dr Sardjito hospital; WHO-
histological classification was done according to the UICC 2002
criteria and EBV-encoded small RNA (EBER) staining was done
with commercial reagents according to the manufacturer’s
instructions (Dako, PNA-kit). Other inclusion criteria were
measurable disease and a curative intent treatment plan. Patients
were not eligible if they had NPC as a second malignancy.
Treatment
Due to different health insurances of the patients, different
treatment regimens have been administered. All patients received
66–70 Gray (Gy) (2 Gy per fraction for 5 days) external beam
radiotherapy and in all cases treatment planning was 2 dimen-
sional. The type of chemotherapy and the number of courses, and
whether applied concurrent or as neo-adjuvant, was adjusted for
the type of insurance and waiting time for radiotherapy at that
time. Options of chemotherapy include 3–4 cycles cisplatinum-
based induction chemotherapy and chemo-concurrent radiother-
apy (CCRT). In induction setting either cisplatin and 5
fluorouracil (5 FU) (PF regimen) or combination of docetaxel,
cisplatin and 5 FU (TPF regimen) are administered. Radiotherapy
is carried out 1 month after induction chemotherapy. During the
course of radiotherapy some patients also received a 6–7 cycles of
weekly carboplatin AUC 2. In the setting of CCRT, a weekly 6–7
cycles of low-dose platinum (40 mg/m2) cooperated with radio-
therapy. Duet o the poor physical condition of some patients with
a advanced stage of disease, it was not possible to treat these
patients with CCRT Rafter neoadjuvant chemotherapy.
Therapy Assessment
Eight weeks after treatment the response was monitored by CT-
scan, chest X-ray, ultrasound of the abdomen and bone survey. In
case of histological proven local persistent or recurrent disease
patients were offered to be treated with photodynamic therapy
(PDT). In case of persistent neck lymph nodes patient were treated
with a modified radical neck dissection.
Follow Up
All patients had a regular follow-up schedule consisting of 3
monthly visits during the first two years after radiotherapy. In case
of suspicion for tumour recurrence radiological examinations were
performed. In case of a local or regional recurrence patients were
treated with photodynamic therapy (PDT) with separate treatment
of the neck.
Photodynamic Therapy (PDT)
Drug administration of FoscanH, light administration and
treatment procedures of the PDT are completely similar to and
described previously in Nyst et al 2012 [14].
Patients received the dose level and the drug light interval
recommended for the treatment of patients with squamous-cell
carcinoma of the head and neck. These parameters are drug dose,
0.15 mg/kg FoscanH; drug-light interval: 48 or 96 hours; light
dose: 20 J/cm2.
Statistical Methods
The association between treatment type (CCRT vs other) and
response (CR vs non-CR) was assuessed using the univariate
Fisher exact test and multivariable logistic regression, adjusting for
sex (male vs. female), type of insurance (poor vs. government vs.
self finance) and AJCC stage (I–II vs III vs IV). In this analysis
patients not receiving treatment were excluded, and patients for
which no tumor assessment was available were assumed to be non-
responders. A sensitivity analysis is performed excluding patients
for which no tumor assessment was available. In these analyses the
level of significance was set at 0.05. Overall (OS) and disease free
survival (DFS) durations were calculated from date of diagnosis of
NPC. For OS duration was until date of death from any cause or
date, while for DFS duration was until development of recurrence
or death from any cause. In both cases in the absence of an event
patients were censored at the date of last contact. The Kaplan-
Meier technique was used to estimate survival. All analyses were
performed using the R-software version 2.15.2.
Results
In total 188 patients presented with NPC during September
2008 till January 2011. Seventy-eight patients were included for
treatment analysis, as they were considered able to complete
treatment protocol based on intake counselling. The median age
of the patients was 49 years (range 17–78), 50 patients were
male and 28 were female patients. Only 2 patients had early
stage disease at entry being stage I or IIA, and 76 patients
presented with loco-regional advanced stage IIB and higher. All
78 patients had an EBER-positive, histological proven NPC and
were WHO type III. Reasons for exclusion were insufficient
funding to afford a curative treatment (n = 27; 25%), no
sufficient funding to afford staging procedures (n = 24, 22%),
no pathology available (n = 24, 22%), decided to go for
traditional treatments (n = 16, 15%), eleven patients presented
with distant metastasis at diagnosis (n = 11, 10%), six patients
due to logistic reasons (7%) and two refused the protocol (2%).
Patient characteristics are listed in table 1. Types of chemo-
therapy regimen administered are listed in table 2.
Radiotherapy
The median time between diagnosis and start of radiotherapy is
120 days (range 13–500). Twelve (15%) patients died before the
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start of radiotherapy due to disease progression or in two cases due
to side effects of the neo-adjuvant chemotherapy treatment. Four
patients did not return for radiotherapy due to concern about the
side effects after the neo-adjuvant chemotherapy and two patients
Table 1. Patient characteristics and type of treatment.
None* Concurrent+RT Neo Adjuvant+Concurrent+RT Neo Adjuvant+RT RT All
N=8 N=18 N=9 N=41 N=2 N=78
Age
Median 48 49 45 51 38 49
(Range) (41–72) (17–73) (27–54) (23–78) (29–47) (17–78)
Sex
F 1 (12%) 8 (44%) 2 (22%) 16 (39%) 1 (50%) 28 (36%)
M 7 (88%) 10 (56%) 7 (78%) 25 (61%) 1 (50%) 50 (64%)
T stage
T1 2 (25%) 2 (11%) 1 (11%) 10 (24%) 1 (50%) 16 (21%)
T2A 1 (12%) 2 (11%) 0 (0%) 5 (12%) 0 (0%) 8 (10%)
T2B 0 (0%) 4 (22%) 1 (11%) 5 (12%) 1 (50%) 11 (14%)
T3 1 (12%) 7 (39%) 7 (78%) 17 (41%) 0 (0%) 32 (41%)
T4 4 (50%) 3 (17%) 0 (0%) 4 (10%) 0 (0%) 11 (14%)
N stage
N0 0 (0%) 1 (6%) 2 (22%) 5 (12%) 1 (50%) 9 (12%)
N1 3 (38%) 6 (33%) 1 (11%) 4 (10%) 1 (50%) 15 (19%)
N2 0 (0%) 8 (44%) 2 (22%) 12 (29%) 0 (0%) 22 (28%)
N3A 2 (25%) 3 (17%) 3 (33%) 15 (37%) 0 (0%) 23 (29%)
N3B 3 (38%) 0 (0%) 1 (11%) 5 (12%) 0 (0%) 9 (12%)
AJCC stage
0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (50%) 1 (1%)
IIA 0 (0%) 0 (0%) 0 (0%) 1 (2%) 0 (0%) 1 (1%)
IIB 0 (0%) 3 (17%) 1 (11%) 1 (2%) 1 (50%) 6 (8%)
III 0 (0%) 9 (50%) 4 (44%) 15 (37%) 0 (0%) 28 (36%)
IVA 3 (38%) 3 (17%) 0 (0%) 3 (7%) 0 (0%) 9 (12%)
IVB 5 (62%) 3 (17%) 4 (44%) 21 (51%) 0 (0%) 33 (42%)
Type of insurance
Government Insurance 0 (0%) 1 (6%) 3 (33%) 1 (2%) 1 (50%) 6 (8%)
Poor Insurance 7 (88%) 17 (94%) 3 (33%) 39 (95%) 0 (0%) 66 (85%)
Self Finance 1 (12%) 0 (0%) 3 (33%) 1 (2%) 1 (50%) 6 (8%)
*The 8 patients who haven’t received any treatment died before the start of treatment.
doi:10.1371/journal.pone.0063706.t001
Table 2. Type of chemotherapy administered.
Concurrent+RT Neo Adjuvant+Concurrent+RT Neo Adjuvant+RT All
N=18 N=9 N=40 N=78
Neoadjuvant chemotherpy
Carboplatin, 5 FU 2 (5%) 2 (3%)
Cisplatin, 5 FU 36 (88%) 36 (46%)
Docetaxel, Cisplatin, 5 FU 9 (100%) 1 (2%) 10 (13%)
Paclitaxel, Cisplatin 1 (2%) 1 (1%)
Concurrent chemotherapy
Carboplatin 1 (6%) 7 (78%) 8 (10%)
Cisplatin 17 (94%) 1 (11%) 18 (23%)
doi:10.1371/journal.pone.0063706.t002
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had, despite counselling, insufficient funding to be treated with
radiotherapy.
Forty-eight (62%) patients eventually finished all fractions of
radiotherapy. The median duration of the radiotherapy is 62 days
(range 46–140 days) for 66 Gy.
Response to Treatment
Twenty three (29%) patients died of disease progression before
treatment response could be assessed. Five patients dropped out
due to insufficient funding, 5 stopped treatment early due to side
effects and 6 stopped treatment due to concern for side effects.
Eventually 39 (50%) patients had a treatment response measure-
ment 8 weeks after treatment. Twenty-three (29%) achieved a
complete response. Ten patients experienced local persistent
disease, in two patients regional persistent disease was found and
two patients developed distant metastasis. Two patients had local
and regional persistent disease, one of them also developed distant
metastasis. The improvement in response rate after receiving
concurrent chemo-radiotherapy was significant (p = 0.002). Ad-
justing for sex, insurance type and AJCC stage did not change this
result (p = 0.001), nor did the exclusion of patients non-evaluable
for response (univariate p = 0.02; multivariable p = 0.02).
Survival
Median overall survival is 21 months (95% CI: 18–35) from day
of diagnosis. The median disease free survival from day of
diagnosis is 20 months (95% CI: 18–24). In figure 1A and figure 1B
Kaplan Meijer curves present the survival probability for overall
survival and disease free survival respectively.
Photodynamic Therapy
Six patients with local persistent disease, which was discovered
during therapy assessment after fulfilment of the regular treatment,
and one patient with a local recurrence, discovered during follow
up, has been treated with PDT. All patients had a complete
response 12 weeks after illumination, three patients developed
regional recurrences and one patient died due to the regional
recurrence.
Discussion
The results presented here reveal that currently the treatment of
NPC at an Indonesian academic hospital is not sufficient and
cannot be compared to the treatment results in literature [11,12].
Of the patients evaluable for response only 29% had a complete
response directly after treatment, with the median overall survival
being 21 months after diagnosis. Main reasons for these poor
treatment results are (1) a long waiting time prior to the start of
radiotherapy, (2) the extended overall duration of radiotherapy
and (3) the advanced stage of disease at presentation.
Cancer is becoming a growing problem in low and middle-
income countries. Since it is ill-defined how many of the patients
actually make it to the hospital and receive a biopsy that is
registered, the actual NPC incidence remains unclear. NPC is the
commonest head and neck cancer in Indonesia with most patients
presenting with an advanced stage of disease which poses a heavy
burden on the population. A major problem is that patients cannot
afford treatment or are afraid of treatment toxicity, causing them
to refrain from treatment or seek alternative options. This resulted
in nearly 61% of the excluded NPC patients being non-compliant
with the inclusion criteria for this study. However, the NPC
treatment results presented here reveal an additional problem, this
being the limited capacity for proper treatment. In 2008 there
were 18 linear accelerators and 17 Cobalt-60 teletherapy machines
available in Indonesia with a population of 229 million,
nevertheless 6 of them were under commission. Resulting in
0.13 accelerator per million inhabitants [15]. This in comparison
to Europe were 5.5 accelerator is available per million inhabitants
in the high, 3.5 per million in the medium and 2 per million in the
low resource countries [16]. The recommended number of
treatment units per population differs widely, in Europe guidelines
of 25 low to high income countries recommended on average 5.9
per million [17].
Although Indonesia is a rising economy, meeting these criteria
will not be feasible on short term. Expanding radiotherapy
facilities is a time and money-consuming project. For building a
new radiotherapy facility and have it installed for treatment the
average time is approximately 5 years. Expansion of staffing
(radiation oncologists, physicists, technologists) takes even longer,
since proper education and training is necessary [16].
When patients with poor insurance in Yogyakarta finally
complete diagnosis and imaging to stage the disease, they have
to wait on average 4 months to start radiotherapy treatment. At
this time 13% have already succumbed to disease progression.
Despite optimal counselling in this study cohort, five patients who
started treatment did not finish the treatment properly because
Figure 1. Kaplan Meijer curves present the survival probability for overall survival and disease free survival respectively.
doi:10.1371/journal.pone.0063706.g001
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they could not afford the costs of the entire treatment.
Importantly, we noted that most patients who eventually started
treatment received insufficient radiotherapy treatment. Optimally,
a total dose of 66 to 70 Grey should be given in 33 to 35 fractions
and the best therapy response is achieved when the total dose is
administered in 45 to 47 days. Every day the radiotherapy is
postponed a loss of the effective dose occurs. This will influence the
treatment success to a great extent [18,19].
The median duration of radiotherapy treatment in this study
was 62 days. This prolonged treatment time together with the 2-
dimensional radiotherapy technique based on CT imaging only
(i.e. not using MRI to assess disease extent) are the main causes of
the poor response rate [20,21]. In part this prolonged treatment
duration is often caused by the radiotherapy facility being
intermittently operational, due to poor maintenance of the
equipment. Other causes for this delay may be due to poor
efficiency in administration and communication at and between
hospital departments and poor patient and doctor compliance to
protocols and timelines. Further research is required to reveal
these causes and can eventually contribute to improve overall
treatment time.
The late stage of NPC at presentation in the hospital is another
unfavourable prognostic factor. One possible reason for the high
percentage of patients with advanced NPC could be due to poor
diagnosis by general practitioners (GP) and thereby a delay in
referral. In our previous study we assessed the knowledge on NPC
of the GPs working in the Primary Health Care Centres in the
Yogyakarta region [22]. Our results indicate that the knowledge of
GPs is insufficient, with many of them not being aware of the high
incidence of NPC in their region.
In Malaysia prior studies have proved that the lack of awareness
and knowledge of primary health care workers is one of the main
reasons for delayed diagnosis [23]. Given that presenting stage is
the most important prognostic factor, appropriate training of GPs
is critical. The relevance of adequate referral by GPs for head and
neck carcinomas has been shown by Alho et al. [24], who found
that 20% of 221 patients, subsequently to being diagnosed with
head and neck carcinoma, were initially sent home without
referral. The risk of death in this group was significantly higher
when compared with the patients who were immediately referred
or received a follow up appointment.
The same group from Finland, has also shown that the time
between GP referral and final diagnosis is a significant factor in
patient outcome in other head and neck cancer [25]. Long delay
in primary care resulted in a significantly worse prognosis in
patients with laryngeal carcinoma [26].
All patients analysed in the presented study had WHO type III
positive NPC. Prior studies have shown that EBV-related markers
can be used for screening and prognostic monitoring. These
markers include EBV (IgA) serology and EBV-DNA load in
nasopharyngeal brushings or blood. NPC patients have charac-
teristic aberrant IgG and IgA antibody reactivity to several EBV
encoded antigens as well as increased EBV-DNA in blood plasma,
derived from shed (apoptotic) tumour fragments into the
circulation. Increased IgA antibody levels are found against early
antigen (EA), viral capsid antigen (VCA) and the latent Epstein-
Barr nuclear antigen 1 (EBNA1) as well as inhibitory antibodies to
the EBV specific DNAse [27,28]. These antibody responses
against defined viral antigens are the basis of a proposed screening
test for NPC in high-risk populations [29–31]. Recent insight in
the molecular basis and diversity of anti EBV IgA and IgG
responses allowed the development of more defined serological
tools [32–36]. Importantly, such initial NPC-risk analysis can be
done in the regional hospital setting with small volumes of blood,
collected by finger prick sampling on filter paper, thus providing a
cheap approach [35,37]. The fingerpick sample might also allow
EBV-DNA load measurement, since DNA is a rather stable
molecule in dried blood. Furthermore, the nasopharyngeal
brushing with EBV marker assessment, may provide a promising
method for detecting tumour presence in situ, by measuring EBV-
DNA and RNA in parallel. Such brushings can be taken with
simple tools under nasal-endoscope guidance [38–42].
Future education programs should include referencing to the
available improved EBV-based diagnostic procedures for NPC-
risk screening and early detection. Improved education combined
with a screening method could be a cheap and sensitive screening
method for NPC in Indonesia and other high incidence countries.
Application of these methods in patients with chronic complaints
in the head and neck, not responding to traditional antibiotic and
anti-allergic medication has already yielded successful detection of
early stage NPC cases in the Sardjito hospital patient population
[43].
Currently we enrolled NPC awareness programme in Jakarta,
Yogyakarta and Surabaya. Short time efficacy of the training
programmes have been published recently [44]. Hopefully in the
future this programme can be expanded to include more regions of
Indonesia.
The patients treated with PDT participate in an ongoing phase
II trial, the results on PDT treatment for persistent and recurrent
disease will be presented in more detail when the study has been
completed. Still worth mentioning is that out of the seven patients
who were treated with PDT, six of them are still alive. This is 17
per cent of all included NPC patients who are still alive. Based on
our experiences and taking into account the poor treatment results
currently for primary NPC in Indonesia, we assume that PDT can
successfully be used in the future as part of the primary treatment.
We hypothesize that PDT can be applied for NPC during the
waiting time for radiotherapy, without compromising the options
for all other possible treatment modalities. Perhaps the physical
condition of the patients remains in such a good condition that at
time the treatment can start patient can receive CCRT, which
showed to have the best improved response rate.
The easiest ways of addressing current problems would be
establishing sufficient radiotherapy facilities in Indonesia, however
this will take decades. In the mean while our goal has to be to
assure that patients who will be treated have an effective treatment
and the right candidates are selected. Early detection of NPC, new
treatment regimens to overcome the waiting time, a counselling
system that supports only those patients who have a real
opportunity to complete the treatment and improved maintenance
for the radiotherapy facility are feasible short-term solutions to
improve treatment outcome in the near future.
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